OBJECTIVE: To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI). DESIGN: : The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data. SETTING: Community. PARTICIPANTS: The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-∊ (APOE) genotyping. MEASUREMENTS: The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status. RESULTS: : Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis. CONCLUSIONS: Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process.
OBJECTIVE: To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI). DESIGN: : The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data. SETTING: Community. PARTICIPANTS: The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-∊ (APOE) genotyping. MEASUREMENTS: The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status. RESULTS: : Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis. CONCLUSIONS: Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process.
Authors: R A Sweet; R L Hamilton; O L Lopez; W E Klunk; S R Wisniewski; D I Kaufer; M T Healy; S T DeKosky Journal: Int Psychogeriatr Date: 2000-12 Impact factor: 3.878
Authors: Robert A Sweet; Kanagasabai Panchalingam; Jay W Pettegrew; Richard J McClure; Ronald L Hamilton; Oscar L Lopez; Daniel I Kaufer; Steven T DeKosky; William E Klunk Journal: Neurobiol Aging Date: 2002 Jul-Aug Impact factor: 4.673
Authors: Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp Journal: Neuroepidemiology Date: 2003 Jan-Feb Impact factor: 3.282
Authors: Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet Journal: J Clin Psychiatry Date: 2016-12 Impact factor: 4.384
Authors: Winnie Qian; Tom A Schweizer; Nathan W Churchill; Colleen Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; David G Munoz; Joseph J Barfett; Tarek K Rajji; Corinne E Fischer Journal: Am J Geriatr Psychiatry Date: 2018-10-02 Impact factor: 4.105
Authors: Su Hee Chu; Kathryn Roeder; Robert E Ferrell; Bernie Devlin; Mary Ann A DeMichele-Sweet; M Ilyas Kamboh; Oscar L Lopez; Robert A Sweet Journal: Neurobiol Aging Date: 2011-08-05 Impact factor: 4.673
Authors: Patrick S Murray; Caitlin M Kirkwood; Megan C Gray; Milos D Ikonomovic; William R Paljug; Eric E Abrahamson; Ruth A Henteleff; Ronald L Hamilton; Julia K Kofler; William E Klunk; Oscar L Lopez; Peter Penzes; Robert A Sweet Journal: Neurobiol Aging Date: 2012-03-17 Impact factor: 4.673
Authors: Lirong Wang; Jian Ying; Peihao Fan; Elise A Weamer; Mary Ann A DeMichele-Sweet; Oscar L Lopez; Julia K Kofler; Robert A Sweet Journal: Am J Geriatr Psychiatry Date: 2019-03-27 Impact factor: 4.105
Authors: Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet Journal: Int Psychogeriatr Date: 2014-03-04 Impact factor: 3.878